209 related articles for article (PubMed ID: 33141487)
1. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?
Massat M; Congy-Jolivet N; Hebral AL; Esposito L; Marion O; Delas A; Colombat M; Faguer S; Kamar N; Del Bello A;
Am J Transplant; 2021 Apr; 21(4):1641-1649. PubMed ID: 33141487
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review.
Cabezas L; Jouve T; Malvezzi P; Janbon B; Giovannini D; Rostaing L; Noble J
Front Immunol; 2022; 13():839380. PubMed ID: 35493469
[TBL] [Abstract][Full Text] [Related]
4. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
Shin BH; Everly MJ; Zhang H; Choi J; Vo A; Zhang X; Huang E; Jordan SC; Toyoda M
Transplantation; 2020 Apr; 104(4):856-863. PubMed ID: 31385933
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
6. Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.
Pearl M; Weng PL; Chen L; Dokras A; Pizzo H; Garrison J; Butler C; Zhang J; Reed EF; Kim IK; Choi J; Haas M; Zhang X; Vo A; Chambers ET; Ettenger R; Jordan S; Puliyanda D
Clin Transplant; 2022 Aug; 36(8):e14734. PubMed ID: 35657013
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
8. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.
Lavacca A; Presta R; Gai C; Mella A; Gallo E; Camussi G; Abbasciano I; Barreca A; Caorsi C; Fop F; Messina M; Rossetti M; Biancone L
Clin Transplant; 2020 Aug; 34(8):e13908. PubMed ID: 32415711
[TBL] [Abstract][Full Text] [Related]
9. Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study.
Montgomery RA; Orandi BJ; Racusen L; Jackson AM; Garonzik-Wang JM; Shah T; Woodle ES; Sommerer C; Fitts D; Rockich K; Zhang P; Uknis ME
Am J Transplant; 2016 Dec; 16(12):3468-3478. PubMed ID: 27184779
[TBL] [Abstract][Full Text] [Related]
10. Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.
Mulley WR; Huang LL; Ramessur Chandran S; Longano A; Amos LAR; Polkinghorne KR; Nikolic-Paterson DJ; Kanellis J
Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640458
[TBL] [Abstract][Full Text] [Related]
11. Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.
Orandi BJ; Lonze BE; Jackson A; Terezakis S; Kraus ES; Alachkar N; Bagnasco SM; Segev DL; Orens JB; Montgomery RA
Am J Transplant; 2016 Oct; 16(10):3041-3045. PubMed ID: 27214874
[TBL] [Abstract][Full Text] [Related]
12. Antibody-mediated rejection: New approaches in prevention and management.
Montgomery RA; Loupy A; Segev DL
Am J Transplant; 2018 Jan; 18 Suppl 3():3-17. PubMed ID: 29292861
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy.
Chamoun B; Sánchez-Sancho P; Torres IB; Gabaldon A; Perelló M; Sellarés J; Moreso F; Serón D
Nefrologia (Engl Ed); 2022; 42(5):578-584. PubMed ID: 36717307
[TBL] [Abstract][Full Text] [Related]
14. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
[TBL] [Abstract][Full Text] [Related]
16. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
[TBL] [Abstract][Full Text] [Related]
18. Acute Antibody-Mediated Rejection in Kidney Transplant Based on the 2013 Banff Criteria: Single-Center Experience in Uruguay.
Nin M; Coitiño R; Kurdian M; Orihuela L; Astesiano R; Garau M; López D; Rievas G; Rodriguez I; González-Martínez F; Noboa O
Transplant Proc; 2016 Mar; 48(2):612-5. PubMed ID: 27110014
[TBL] [Abstract][Full Text] [Related]
19. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
Wan SS; Ying TD; Wyburn K; Roberts DM; Wyld M; Chadban SJ
Transplantation; 2018 Apr; 102(4):557-568. PubMed ID: 29315141
[TBL] [Abstract][Full Text] [Related]
20. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]